Читать книгу Surgical Management of Advanced Pelvic Cancer - Группа авторов - Страница 48

Chemotherapy for LARC has traditionally been fluoropyrimidine‐based. In the postoperative (adjuvant) setting, oxaliplatin improves progression‐free and disease‐free survival in colonic cancer [7]. The role of oxaliplatin in neoadjuvant treatment has been debated. Apart from the German CAO/ARO/AIO‐04 trial [45], several trials and meta‐analyses have failed to demonstrate a survival advantage with oxaliplatin added to radiosensitizing fluoropyrimidine nCRT [46–50].Furthermore, oxaliplatin was associated with significant toxicity including neurotoxicity and increased risk of infection. For TNT, the optimum regimen is unknown (e.g. capecitabine alone, CAPOX, or FOLFOX). Toxicity of treatment regimens is a concern, and poor compliance could be a major challenge if patients do not complete the intended dose‐intensity. Encouragingly, several trials evaluating induction and/or consolidation chemotherapy reported favorable compliance rates of over 90% with toxicity profiles comparable to those of standard nCRT [36, 51, 52]. In the Spanish GCR‐3 study, 91% of patients completed the study protocol in the induction chemotherapy arm compared with 54% in the nCRT/adjuvant chemotherapy arm (p <0.001) [53]. Garcia‐Aguilar et al. reported compliance rates of 77–82% depending on the number of cycles of mFOLFOX given [25]. The two most recent phase 3 TNT trials (RAPIDO and PRODIGE 23) clearly demonstrate that it is safe and efficacious to incorporate oxaliplatin into neoadjuvant chemotherapy regimens. Neither trial included oxaliplatin during radiotherapy.